International Journal of Health Sciences and Research
Volume 14; Issue: 9; September 2024
Website: www.ijhsr.org
Review Article *ISSN: 2249-9571*

The Role of Tyrosine Kinases in Cancer: Signal Transduction Mechanisms and Therapeutic Targets

Aruna Rajeswari[1], Balaprakash Bhavani[2]

[1,2]Department of Medicine, Tbilisi State Medical University, Tbilisi, Georgia

Corresponding Author: Aruna Rajeswari

DOI: https://doi.org/10.52403/ijhsr.20240942

ABSTRACT

Tyrosine kinases are key mediators in cellular signaling, governing essential processes such as growth, differentiation, metabolism, and apoptosis. In cancer, these kinases often become dysregulated due to mutations, overexpression, or autocrine-paracrine signaling, leading to uncontrolled cell proliferation and tumor development. Receptor tyrosine kinases (RTKs), a prominent subset, are frequently implicated in cancer, with many tumors exhibiting dependency on aberrant RTK signaling. This dependency has made RTKs a major focus for targeted cancer therapies, particularly through the development of small molecule tyrosine kinase inhibitors (TKIs). Despite the initial success of these inhibitors in clinical settings, the emergence of resistance remains a significant hurdle, often leading to relapse. Advances in technology are now facilitating the identification of novel RTK inhibitors, aiming to overcome resistance and improve therapeutic outcomes. This abstract highlight the importance of understanding the signal transduction mechanisms of tyrosine kinases and emphasizes their potential as therapeutic targets in the ongoing battle against cancer.

KEY WORDS: *Tyrosine kinase, Cancer, signaling, Inhibitor, drugs*

INTRODUCTION

Significant advancements in cellular biology began in the early 1950s with the discovery of receptor tyrosine kinases (RTKs). Initially recognized as receptors for insulin and epidermal growth factor (EGF), RTKs soon became central to understanding cellular signaling systems. These receptors play crucial roles in various biological processes, including neuron development and cell proliferation, both in vivo and in vitro. By the 1960s, research on insulin furthered understanding of its receptor interactions, leading to key insights into ligand-binding properties. The 1970s brought additional progress, as scientists mapped the binding sites of EGF on cell surfaces and linked protein phosphorylation on tyrosine residues with intracellular signaling, laying the groundwork for cancer research. By the early 1980s, it was well-established that some receptors act as ligand-activated protein tyrosine kinases, underscoring the critical role of RTKs in cellular development, physiological functions, and cancer progression.

Tyrosine kinases, including RTKs, are essential enzymes that mediate signal transduction processes in multicellular organisms, regulating cell proliferation, differentiation, migration, metabolism, and programmed cell death. These enzymes catalyze the phosphorylation of specific tyrosine residues in target proteins using ATP, a process vital for normal cellular communication and homeostasis. However, in cancer, tyrosine kinase signaling pathways are often genetically or epigenetically

altered, leading to deregulated cell proliferation and survival, which contribute to neoplastic development and progression. The discovery of the SRC oncogene with non-receptor tyrosine kinase activity and the identification of EGFR as the first receptor tyrosine kinase paved the way for understanding tyrosine kinases' role in cancer. With the completion of the Human Genome Project, over 90 tyrosine kinases have been identified, many of which are involved in cancer.

The RTK family, which includes a diverse array of cell surface receptors, responds to growth factors, hormones, and cytokines, mediating essential cellular and metabolic signaling pathways. The extracellular domains of these receptors govern ligand binding, receptor activation, and subsequent signaling cascades, making RTKs crucial determinants of cellular responses. Their structural diversity, including features like immunoglobulin-like domains, cysteine-rich regions, and fibronectin type III repeats, leads to their classification into different families, each with unique ligand-binding capabilities. Aberrant signaling from tyrosine kinases, due to enhanced expression, mutation, or autocrine stimulation, transforms these enzymes into dominant oncoproteins that disrupt normal signaling networks. Consequently, the identification and development of therapeutic agents targeting these dysregulated kinases have become a central focus in cancer therapy, offering new avenues for treating various malignancies by inhibiting abnormal oncogenic signaling.

BIOCHEMICAL BASIS OF TYROSINE KINASE SIGNALLING:

Tyrosine kinases are enzymes that specifically phosphorylate tyrosine residues on different substrates. Receptor tyrosine kinases (RTKs) are activated when ligands bind to their extracellular domains. Ligands, such as EGF and PDGF, are extracellular signaling molecules that induce receptor dimerization (except for the insulin receptor, which is pre-dimerized). Different ligands use various strategies to achieve stable dimeric conformations. For instance, some ligands bind to two receptor molecules to form a 1:2 ligand-to-receptor complex, like growth hormone with its receptor. In other cases, two ligands bind simultaneously to two receptors, forming a 2:2 ligand-to-receptor complex, as seen with VEGF and VEGFR, which represents a straightforward mechanism for receptor dimerization. Receptor dimerization is also stabilized by direct interactions between the receptors. In some complexes, ligand binding alone is insufficient for stabilization, requiring additional molecules; for example, FGFs require heparan sulfate proteoglycans (HSPGs) to stabilize and activate FGFR complexes. Ligand binding to the extracellular domain promotes the formation of active dimers, leading to the activation of the receptor's protein tyrosine kinase function.

Structural studies of the catalytic core of several RTKs, along with biochemical and kinetic studies of receptor phosphorylation, have shown that receptor oligomerization increases the local concentration of RTKs. This clustering facilitates efficient transphosphorylation of tyrosine residues in the activation loop of the catalytic domain. Upon tyrosine phosphorylation, the activation loop changes to an open conformation, allowing ATP and substrates to access the active site. This enables the transfer of phosphate groups from Mg-ATP to tyrosine residues on the receptor itself and on cellular proteins involved in downstream signaling pathways.

The ATP-binding intracellular catalytic domain responsible for receptor autophosphorylation is highly conserved among RTKs. The ATP binding site acts as a docking site for cytoplasmic signaling proteins containing Src homology-2 (SH2) and protein tyrosine binding (PTB) domains. These signaling proteins recruit additional effector molecules with SH2, SH3, PTB, and Pleckstrin homology (PH) domains, forming signaling complexes at the activated receptor and membrane. This assembly activates a

cascade of intracellular biochemical signals that ultimately regulate the expression of various genes, defining the biological response to the initial signal.

During the signaling process, receptors move within the plasma membrane and are internalized through clathrin-coated pits, which form endocytic vesicles. These vesicles may fuse with lysosomes, where the receptor and ligand can be degraded by lysosomal enzymes. In some cases, receptors are recycled back to the cell surface. Throughout receptor internalization, the ligand-receptor complex dissociates, leading to the termination of the signaling reaction.

PHYSIOLOGICAL PATHWAYS OF RECEPTOR TYROSINE KINASE ACTIVATION:

Receptor Tyrosine Kinases (RTKs) are activated by receptor-specific ligands, typically growth factors. These ligands bind to the extracellular regions of RTKs, inducing receptor dimerization or oligomerization. This binding results in conformational changes that enable trans-autophosphorylation of the tyrosine kinase domains (TKDs) and the release of cis-autoinhibition. The conformational change allows the TKD to adopt an active state. Autophosphorylation also recruits and activates various downstream signaling proteins that contain Src homology-2 (SH2) or phosphotyrosine-binding (PTB) domains, which bind to specific phosphotyrosine residues within the receptor and propagate critical cellular signaling pathways.

Modes of RTK Dimerization

RTK dimerization can occur through four distinct modes:

Ligand-Mediated Dimerization: Receptor dimerization occurs solely through ligand binding, without direct interaction between the extracellular regions of the receptors. An example is TrkA (NGF receptor).

Receptor-Mediated Dimerization: Dimerization occurs without direct interaction between activating ligands, as seen in the ErbB family members (e.g., EGFR, HER2/ErbB2, HER3/ErbB3, and HER4/ErbB4).

Ligand Homodimer Binding: Homodimers of the ligand bind to two receptor molecules, which then interact across the dimer interface. KIT (SCF receptor) is an example of this mode.

Accessory Molecule Participation: In addition to bivalent ligand binding and direct receptor-receptor contacts, accessory molecules like heparin or heparan sulfate are involved in receptor dimerization. The FGFR family of RTKs exemplifies this mode.

Notably, some RTKs can form dimers or high-order oligomers even in the absence of activating ligands. For instance, EGFR predominantly exists as monomers before ligand binding, while the insulin receptor (IR) exists as pre-formed dimers. Ligand binding shifts the equilibrium towards active dimerization, either by stabilizing pre-formed dimers or inducing conformational changes in inactive dimers.

Activation of ErbB Family RTKs

The ErbB family of RTKs is of particular interest in cancer biology. The extracellular regions of ErbB receptors contain four subdomains (I-IV). In the absence of ligands, the intracellular TKD is inactive, and the extracellular region adopts a “tethered” configuration. The dimerization arm (a β-hairpin within subdomain II) is buried by intra-molecular interactions with domain IV, forming intra-molecular autoinhibitory interactions. Ligand binding to subdomains I and III induces a conformational change that extends the extracellular region and exposes the previously buried dimerization arm. This exposure facilitates receptor dimerization and triggers intracellular conformational changes that enable kinase activation.

Activation of Intracellular Tyrosine Kinase Domains

Before activation, the TKD is in a state of cis-autoinhibition due to specific intra-molecular interactions unique to each receptor:

FGFR, IR, and IGF-1R: Autoinhibited by the activation loop, which disrupts ATP and substrate binding.

KIT and Eph Receptors: Regulated by juxtamembrane autoinhibition, where the juxtamembrane region interacts with the active site of the kinase.
TEK, MET, and RON: The C-terminal tail inhibits the active site of the TKD, stabilizing an inactive conformation.
Ligand-induced dimerization causes trans-phosphorylation of key tyrosine residues, destabilizing these autoinhibitory interactions and allowing the kinase to assume an active conformation.
For the ErbB family, kinase activation occurs through an allosteric mechanism: the C-lobe of one kinase domain (the 'activator') contacts the N-lobe of the other kinase domain (the 'receiver'). This interaction induces conformational changes in the receiver kinase, activating it and causing trans-phosphorylation of tyrosine residues in the activator. Notably, phosphorylation of the activation loop is not involved in this mechanism.

Mechanism of Downstream Signaling
Autophosphorylation of RTKs leads to the recruitment of various downstream signaling proteins. Most of these proteins contain SH2 or PTB domains that bind to the phosphorylated tyrosine residues on RTKs. These proteins can be recruited directly or through docking proteins that serve as assembly platforms. Docking proteins bind to RTKs via their PTB domains and recruit additional signaling molecules. The presence of multiple phosphotyrosines and docking proteins enables RTKs to activate a range of signaling pathways, including RAS/MAPK, PI-3 K/AKT, and JAK2/STAT signaling. RTKs thus act as crucial nodes in transferring extracellular signals to the cell nucleus, regulating cell growth, migration, and other processes.

Summary
In-depth structural and biochemical studies have elucidated the complex mechanisms of RTK activation. Understanding these mechanisms is crucial for grasping how oncogenic mutations in RTKs disrupt normal signaling, leading to dysregulation of cell growth and tumor development.

CLASSIFICATION
Tyrosine kinases are primarily categorized into two groups: receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (NRTKs).

Receptor Tyrosine Kinases (RTKs)
RTKs are cell surface transmembrane receptors that also function as enzymes with kinase activity. Structurally, RTKs consist of three main components:

Extracellular Domain
This domain is responsible for ligand binding and specificity. It often includes multiple domains that interact with various ligands.
Transmembrane Helix
A single-pass hydrophobic helix that spans the cell membrane.

Cytoplasmic Domain
Contains the tyrosine kinase domain and regulatory sequences at both the N- and C-terminal ends. The kinase domain is crucial for the enzymatic activity of RTKs, which involves the phosphorylation of tyrosine residues on target proteins.
Activation of RTKs occurs through ligand binding to the extracellular domain, leading to receptor dimerization. This dimerization facilitates trans-phosphorylation within the cytoplasmic domain, which in turn activates the kinase activity of the receptors.

Non-Receptor Tyrosine Kinases (NRTKs)
NRTKs are cytoplasmic proteins and exhibit significant structural variability. Key features of NRTKs include:

Kinase Domain
Similar to RTKs, the kinase domain of NRTKs spans approximately 300 residues and includes:
N-terminal Lobe: Comprising a five-stranded β-sheet and one α-helix.
C-terminal Lobe: A large, mainly α-helical domain. ATP binds in the cleft between these

two lobes, and the tyrosine-containing sequence of protein substrates interacts with residues in the C-terminal lobe.

Additional Domains

NRTKs often contain several additional signaling or protein-protein interacting domains, such as SH2 (Src Homology 2), SH3 (Src Homology 3), and PH (Pleckstrin Homology) domains.

The activation mechanism of NRTKs is more complex compared to RTKs. It typically involves interactions with other proteins to enable trans-phosphorylation, rather than direct ligand binding and receptor dimerization.

ACTIVATION OF TYROSINE KINASE BY ONCOGENIC MUTATIONS

Under normal physiological conditions, receptor tyrosine kinase (RTK) activity is carefully regulated by various mechanisms, including the action of tyrosine phosphatases. However, RTKs can acquire oncogenic potential through several pathways, ultimately disrupting the balance between cell proliferation and apoptosis. Dysregulated RTK signaling, especially when considering temporal and spatial factors, adds further complexity to this process. Continuous activation of RTKs can endow normal cells with cancerous properties, leading to RTK-driven oncogenesis. There are four main mechanisms that can cause persistent RTK activation in human cancers: gain-of-function mutations, gene amplification, chromosomal rearrangements, and autocrine signaling. This discussion will focus on these four mechanisms, highlighting a specific intragenic event known as kinase domain duplication (KDD).

1. Activation by Gain of Function Mutations

Mutations in receptor tyrosine kinases (RTKs) can lead to constitutive activity, driving cancer progression. For instance, the EGFRvIII mutant lacks amino acids 6-273, resulting in receptor activity without ligand binding, which contributes to uncontrolled cell proliferation in glioblastomas, ovarian tumors, and non-small cell lung carcinoma. Similarly, point mutations in the FGFR3 extracellular domain lead to an unpaired cysteine residue, promoting abnormal receptor dimerization through intermolecular disulfide bonding, observed in multiple myeloma. Somatic mutations in EGFR2 and EGFR3 are associated with human bladder and cervical carcinomas.

2. Overexpression and Genomic Amplification

Overexpression of RTKs and their ligands can cause constitutive activation through autocrine or paracrine loops. In several cancers, such as non-small cell lung cancer, bladder cancer, breast cancer, and glioblastoma multiforme, there is a strong association between the overexpression of EGFR and its ligands EGF and TGFα. Increased EGFR expression is reported in 40-80% of non-small cell lung cancers and 50% of primary lung cancers, with TGFα involvement in 20-40% of lung cancers. PDGFR and its ligands PDGF-A and PDGF-B are overexpressed in astrocytic brain tumors and gliomas. Elevated expression of IGFR and its ligands IGF I and IGF II contributes to the pathogenesis of breast cancer, prostate cancer, and small cell lung cancer, with elevated IGF-I receptor activity noted in breast cancer and increased IGF-I plasma levels linked to higher prostate cancer risk.

3. Chromosomal Rearrangements

Chromosomal rearrangements are a significant mechanism of RTK deregulation. In chronic myelogenous leukemia (CML), a reciprocal translocation between chromosomes 9 and 22 forms the Philadelphia chromosome, resulting in the BCR-ABL fusion gene. This gene encodes a 210 KDa mutant protein with increased tyrosine kinase activity, correlating with the CML phenotype. A different BCR-ABL fusion protein (185 KDa) is observed in 10% of adult acute lymphoblastic leukemia (ALL) cases. The TEL-ABL fusion gene, arising from a translocation t(9;12), is another example, leading to a protein with

constitutive kinase activity in ALL and CML with a complex karyotype (t(9;12;14)). Other notable translocations include TEL-PDGFR (t(5;12)) in chronic myelomonocytic leukemia (CMML) and NPM-ALK (t(2;5)) in anaplastic large cell lymphoma, both causing constitutive kinase activation.

Constitutive activation by kinase domain duplication:

Intragenic partial duplication is a type of chromosomal rearrangement that allows cancer cells to develop new protein isoforms. A specific example of this is kinase domain duplications (KDDs), which provide a unique mechanism for activating receptor tyrosine kinases (RTKs) in tumors. Oncogenic EGFR-KDD and BRAF-KDD have been documented in various human cancers and have shown specific responses to targeted therapies against EGFR and BRAF. Recently, our research team found that EGFR-KDD is a recurrent alteration in non-small cell lung cancer (NSCLC). This duplication was also observed in other cancers such as gliomas, sarcomas, and Wilms' tumor. Similarly, BRAF-KDD has been identified in gliomas and advanced acinic cell tumors. Even though BRAF is a serine/threonine kinase, it is relevant here to illustrate the concept.

A recent study analyzed genomic data from 114,200 human tumors and identified recurrent KDDs in multiple kinases, including the ErbB family (EGFR, ERBB2, and ERBB4), the FGFR family (FGFR1, FGFR2, and FGFR3), the NTRK family (NTRK1 and NTRK2), and the PDGFR family (PDGFRA and PDGFRB), along with other kinases such as BRAF, RET, MET, ROS1, ALK, and KIT. In brain tumors, KDDs most frequently involved EGFR, BRAF, PDGFRA, and FGFR3, while in extracranial tumors, KDDs were more common in RET, MET, and ALK genes. Overall, KDD alterations were found in about 0.62% of the cases (598 KDDs out of 114,200 cases).

In nature, gene duplication is a mechanism that can provide genetic diversity or redundancy, allowing organisms to adapt to different environmental conditions. Similarly, in cancer cells, KDDs might be selected for as a response to the selective pressure from cancer therapies. For instance, BRAF-KDD has been identified as a new mechanism of resistance to BRAF inhibitors in melanoma patients. The detection of EGFR-KDD amplification in post-treatment biopsies suggests its role in acquired resistance to the EGFR tyrosine kinase inhibitor (TKI), afatinib.

The most extensively studied KDD so far is EGFR-KDD. Normally, wild-type EGFR activation by its ligands involves the formation of an asymmetric dimer between two receptor molecules. However, EGFR-KDD, which contains two in-frame tyrosine kinase domains arranged in tandem, may activate through constitutive intra-molecular dimerization, leading to ligand-independent signaling. Preclinical studies, both in silico and in vitro, have confirmed this potential activation mechanism. This differs from the activation mechanisms of other EGFR kinase domain mutants, such as L858R and exon 19 deletions, highlighting how genomic alterations can change protein structure and function to create oncogenic variants.

For BRAF-KDD, most genomic breakpoints occur within intron 9 of BRAF, resulting in a truncated protein capable of dimerizing in a RAS-independent manner. This suggests that different KDDs may use distinct activation mechanisms, underscoring the need for systematic functional studies of each novel KDD within RTKs to fully understand the RTK activation paradigm.

4. Autocrine Activation

Autocrine and paracrine stimulation is a key mechanism for RTK activation, particularly when the receptor and its ligand are abnormally or overexpressed together. EGFR and its primary ligands, EGF and TGFα, exhibit strong autocrine loops in many cancers, including non-small cell lung cancer, bladder cancer, breast cancer, and glioblastoma multiforme. PDGFR and its ligands (PDGF-A and PDGF-B) show similar co-expression in astrocytic brain tumors and gliomas. Insulin-like growth

factor receptors (IGFR) and their ligands (IGF I and IGF II) participate in autocrine loops contributing to the development of breast cancer, prostate cancer, and small cell lung cancer.

TYROSINE KINASE IN CANCER TREATMENT

The role of tyrosine kinases in cancer pathogenesis is substantial, and these enzymes have recently gained attention as potential targets for anticancer drugs. With the advancements from the Human Genome Project, the complexity and number of tyrosine kinases have increased, offering new avenues for drug discovery. Recent insights into cancer biology have revealed that many tyrosine kinases are located upstream or downstream of significant oncogenes or tumor suppressor genes, particularly receptor tyrosine kinases.

Targeting Sites

The field of cancer research saw significant progress following the enactment of The National Cancer Act (1971) by President Richard Nixon. By the late 1980s, there was evidence supporting the use of low molecular weight tyrosine kinase inhibitors. These inhibitors can interfere with either ligand binding (for receptor tyrosine kinases) or with protein substrates (for non-receptor tyrosine kinases). Despite early promise, bisubstrate inhibitors and non-competitive or allosteric inhibitors have seen limited practical success. ATP-competitive inhibitors have become the preferred approach.

ATP Binding Site

ATP binds within a cleft formed between the two lobes of the tyrosine kinase domain. Although the ATP binding site is highly conserved, the regions around it offers diversity that can be exploited for drug design. Key features of the ATP binding site include:

Adenine Region: Contains two critical hydrogen bonds involving the N-1 and N-6 amino groups of the adenine ring, which many potent inhibitors target.

Sugar Region: Typically hydrophilic, with some exceptions such as EGFR. This region, along with the hydrophobic pocket, plays a role in inhibitor selectivity.

Hydrophobic Channel: Not utilized by ATP but can be targeted to enhance inhibitor specificity.

Phosphate Binding Region: Can be leveraged to improve the selectivity of inhibitors.

Small Molecule Inhibitors

Tyrosine kinases are crucial in many oncoproteins, making them key targets for cancer therapy. Low molecular weight inhibitors, known as tyrphostins, have shown promise in blocking cell proliferation. By the late 1980s, it was demonstrated that low molecular weight EGFR inhibitors could inhibit EGF-dependent cell growth. Research has since revealed that some tyrosine kinase inhibitors are ATP mimics. Many tyrphostins with aromatic rings can be converted into ATP mimics by incorporating specific structures. ATP mimics often have at least two aromatic rings. The evolutionary conservation of the ATP binding site allows for selective targeting due to minor differences in the kinase domain, which affect hydrogen bonding and hydrophobic interactions. Successful tyrosine kinase inhibitors include Gleevec, Iressa, and Tarceva. Gleevec (Imatinib mesylate) is effective against CML and c-kit positive metastatic GIST by selectively inhibiting the BCR-ABL fusion protein. Iressa targets the EGF receptor tyrosine kinase in non-small cell lung cancer and squamous cell carcinoma. The mTOR pathway, involved in abnormal cellular growth, is inhibited by rapamycin and CCI779, which are currently in phase II trials.

Monoclonal Antibodies

The extracellular domain of receptor tyrosine kinases is a prime target for monoclonal antibodies. Advances in genomics have facilitated the design and production of

therapeutic monoclonal antibodies, including humanized, human chimeric, or bispecific antibodies. The EGFR family, which includes EGFR/ErbB1, HER-2/ErbB2, HER-3/ErbB3, and HER-4/ErbB4, plays a significant role in cancer biology. Overexpression of EGFR and HER-2 is associated with several cancers. Herceptin (Trastuzumab) is a notable example of a targeted therapy for HER-2 positive breast cancer. It inhibits cell cycle progression and induces an immune response. Rituximab targets CD20 and is effective against Non-Hodgkin's Lymphoma.

EGFR overexpression is common in various cancers, and monoclonal antibodies like C225 (cetuximab) and 2C4 target specific EGFR family members. Anti-VEGF monoclonal antibodies, which block angiogenesis, are also promising for cancer therapy. Antibodies targeting overexpressed antigens, like the P12 antigen, may offer new treatment options.

Hsp90 and Novel Strategies

Heat shock proteins (Hsp) are crucial for maintaining cellular homeostasis and protein folding, and their accumulation is often seen in tumors. Inhibitors targeting Hsp90 can destabilize kinases and promote their degradation, reducing kinase levels. Notable examples include Geldanamycin, Cisplatin, and Radicol, which affect various oncogenic proteins.

Antibody-Drug Conjugates

Immunotherapy is gaining traction, with efforts to enhance the efficacy of antibodies by conjugating them with toxins. Immunotoxins, such as DAB389EGF, combine specific antibodies with diphtheria toxin to target cancer cells. Other antibody-drug conjugates, like Tositumomab and anti-Tac(Fv)-PE38(LMB-2), show promise in treating lymphomas and other cancers. Advances in genomics and proteomics are driving the development of more effective antibody-drug conjugates.

Antisense Strategies and Peptide Drugs

Antisense oligonucleotides are designed to bind to mRNA and block protein translation. For instance, antisense oligodeoxynucleotides targeting IGF-1R have shown efficacy in melanoma and breast cancer. Peptides and peptidomimetics that interfere with protein-protein interactions, such as those targeting Grb2-Sos interactions, are also being explored as potential therapies.

Angiogenesis Inhibitors

Angiogenesis, the formation of new blood vessels from existing ones, is crucial for tumor growth and metastasis. Targeting angiogenesis can be an effective cancer treatment strategy. Inhibitors like SU5416 and PD173074 target VEGF and FGFR1, while PD98059 inhibits the MAPK cascade. Antiangiogenic therapies help limit tumor blood supply, reducing growth and spread, and may offer long-term treatment benefits due to reduced drug resistance.

FUTURE CHALLENGES

Receptor tyrosine kinases (RTKs) are central to cancer progression, and targeting oncogenic mutations within these kinases has significantly advanced cancer treatment. While this manuscript does not provide a comprehensive review of all RTK inhibitors, it is notable that numerous small-molecule inhibitors have been created to address cancers and other conditions associated with RTK mutations. These inhibitors primarily act on the ATP-binding site of the tyrosine kinase domain. The FDA has also approved several monoclonal antibodies that inhibit RTK activation, such as cetuximab for lung cancer, panitumumab for colon cancer, cetuximab for head and neck cancer, and trastuzumab and pertuzumab for breast cancer. The integration of these targeted therapies, including tyrosine kinase inhibitors (TKIs) and monoclonal antibodies, has marked a significant shift toward precision medicine in oncology. Despite these advancements, the emergence of acquired resistance to these therapies is a

common challenge. Resistance can arise due to genetic mutations or the activation of alternative signaling pathways. To address this issue, new strategies have been developed, such as second-generation and third-generation inhibitors, as well as the combination of TKIs with monoclonal antibodies targeting the same RTK.

CONCLUSION

Tyrosine kinases play a crucial role in regulating cellular growth and differentiation, and their dysfunction is implicated in various human cancers. The success of tyrosine kinase inhibitors such as Gleevec, Iressa, and Herceptin highlights their potential in clinical settings. Numerous tyrosine kinase inhibitors are currently in clinical trials, and many more are under development. However, these therapies are primarily effective against cancers with specific kinase alterations, posing challenges for their broader application. To address these challenges, there is a need for rapid identification of clinically relevant, druggable tyrosine kinase targets, along with more efficient lead discovery and optimization. Advances in high-throughput cancer genomics and molecular therapeutics are essential to making progress in this area. Such efforts could ultimately lead to the development of personalized cancer treatments tailored to individual patient profiles.

Declaration by Authors

Ethical Approval: None required
Acknowledgement: None
Source of Funding: None
Conflict of Interest: None

REFERENCES

1. Paul, M. K., & Mukhopadhyay, A. K. (2004). Tyrosine kinase – Role and significance in Cancer. International Journal of Medical Sciences, 101–115. https://doi.org/10.7150/ijms.1.101
2. Saraon, P., Pathmanathan, S., Snider, J., Lyakisheva, A., Wong, V., & Stagljar, I. (2021). Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches. Oncogene, 40(24), 4079–4093. https://doi.org/10.1038/s41388-021-01841-2
3. Tomuleasa, C., Tigu, A. B., Munteanu, R., Moldovan, C. S., Kegyes, D., Onaciu, A., Gulei, D., Ghiaur, G., Einsele, H., & Croce, C. M. (2024). Therapeutic advances of targeting receptor tyrosine kinases in cancer. Signal Transduction and Targeted Therapy, 9(1). https://doi.org/10.1038/s41392-024-01899-w
4. Hunter, T. (2000). Signaling—2000 and Beyond. Cell, 100(1), 113–127. https://doi.org/10.1016/s0092-8674(00)81688-8
5. Schlessinger, J. (2000). Cell Signaling by Receptor Tyrosine Kinases. Cell, 103(2), 211–225. https://doi.org/10.1016/s0092-8674(00)00114-8
6. Blume-Jensen, P., & Hunter, T. (2001). Oncogenic kinase signalling. Nature, 411(6835), 355–365. https://doi.org/10.1038/35077225
7. Hunter, T., & Cooper, J. A. (1985). PROTEIN-TYROSINE KINASES. Annual Review of Biochemistry, 54(1), 897–930. https://doi.org/10.1146/annurev.bi.54.070185.004341
8. Carpenter, G., King, L., & Cohen, S. (1978). Epidermal growth factor stimulates phosphorylation in membrane preparations in vitro. Nature, 276(5686), 409–410. https://doi.org/10.1038/276409a0
9. Pestell, K. E. (2003). Paul Workman on the challenges of cancer drug development. Drug Discovery Today, 8(17), 775–777. https://doi.org/10.1016/s1359-6446(03)02838-1
10. Sawyers, C. (2002b). Rational therapeutic intervention in cancer: kinases as drug targets. Current Opinion in Genetics & Development, 12(1), 111–115. https://doi.org/10.1016/s0959-437x(01)00273-8
11. Cohen, S. (1962). Isolation of a Mouse Submaxillary Gland Protein Accelerating Incisor Eruption and Eyelid Opening in the New-born Animal. Journal of Biological Chemistry, 237(5), 1555–1562. https://doi.org/10.1016/s0021-9258(19)83739-0
12. Levi-Montalcini, R., & Booker, B. (1960). EXCESSIVE GROWTH OF THE SYMPATHETIC GANGLIA EVOKED BY A PROTEIN ISOLATED FROM MOUSE

SALIVARY GLANDS. Proceedings of the National Academy of Sciences, 46(3), 373–384. https://doi.org/10.1073/pnas.46.3.373

13. De Meyts, P., Roth, J., Neville, D. M., Gavin, J. R., & Lesniak, M. A. (1973). Insulin interactions with its receptors: Experimental evidence for negative cooperativity. Biochemical and Biophysical Research Communications, 55(1), 154–161. https://doi.org/10.1016/s0006-291x(73)80072-5
14. Carpenter, G., & Cohen, S. (1976). 125I-labeled human epidermal growth factor. Binding, internalization, and degradation in human fibroblasts. The Journal of Cell Biology, 71(1), 159–171. https://doi.org/10.1083/jcb.71.1.159
15. Ushiro, H., & Cohen, S. (1980). Identification of phosphotyrosine as a product of epidermal growth factor-activated protein kinase in A-431 cell membranes. Journal of Biological Chemistry, 255(18), 8363–8365. https://doi.org/10.1016/s0021-9258(18)43497-7
16. Kasuga, M., Zick, Y., Blithe, D. L., Crettaz, M., & Kahn, C. R. (1982). Insulin stimulates tyrosine phosphorylation of the insulin receptor in a cell-free system. Nature, 298(5875), 667–669. https://doi.org/10.1038/298667a0
17. De Meyts, P. (2014). Receptor Tyrosine Kinase Signal Transduction and the Molecular Basis of Signalling Specificity. In Springer eBooks (pp. 51–76). https://doi.org/10.1007/978-1-4939-2053-2_4
18. Zhao, M., Jung, Y., Jiang, Z., & Svensson, K. J. (2020). Regulation of Energy Metabolism by Receptor Tyrosine Kinase Ligands. Frontiers in Physiology, 11. https://doi.org/10.3389/fphys.2020.00354
19. Vaparanta, K., Jokilammi, A., Tamirat, M., Merilahti, J. a. M., Salokas, K., Varjosalo, M., Ivaska, J., Johnson, M. S., & Elenius, K. (2022). An extracellular receptor tyrosine kinase motif orchestrating intracellular STAT activation. Nature Communications, 13(1). https://doi.org/10.1038/s41467-022-34539-4
20. Gonzalez-Magaldi, M., McCabe, J. M., Cartwright, H. N., Sun, N., & Leahy, D. J. (2020). Conserved roles for receptor tyrosine kinase extracellular regions in regulating receptor and pathway activity. Biochemical Journal, 477(21), 4207–4220. https://doi.org/10.1042/bcj20200702
21. Yao, Z., & Stagljar, I. (2017). Multiple functions of protein phosphatases in receptor tyrosine kinase signaling revealed by interactome analysis. Molecular & Cellular Oncology, 4(3), e1297101. https://doi.org/10.1080/23723556.2017.1297101
22. Schlessinger, J. (2000b). Cell Signaling by Receptor Tyrosine Kinases. Cell, 103(2), 211–225. https://doi.org/10.1016/s0092-8674(00)00114-8
23. Lemmon, M. A., & Schlessinger, J. (2010b). Cell Signaling by Receptor Tyrosine Kinases. Cell, 141(7), 1117–1134. https://doi.org/10.1016/j.cell.2010.06.011
24. Pawson, T., Gish, G. D., & Nash, P. (2001). SH2 domains, interaction modules and cellular wiring. Trends in Cell Biology, 11(12), 504–511. https://doi.org/10.1016/s0962-8924(01)02154-7
25. Wehrman, T., He, X., Raab, B., Dukipatti, A., Blau, H., & Garcia, K. C. (2007). Structural and Mechanistic Insights into Nerve Growth Factor Interactions with the TrkA and p75 Receptors. Neuron, 53(1), 25–38. https://doi.org/10.1016/j.neuron.2006.09.034
26. Zhang, X., Gureasko, J., Shen, K., Cole, P. A., & Kuriyan, J. (2006). An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor. Cell, 125(6), 1137–1149. https://doi.org/10.1016/j.cell.2006.05.013
27. Yuzawa, S., Opatowsky, Y., Zhang, Z., Mandiyan, V., Lax, I., & Schlessinger, J. (2007). Structural Basis for Activation of the Receptor Tyrosine Kinase KIT by Stem Cell Factor. Cell, 130(2), 323–334. https://doi.org/10.1016/j.cell.2007.05.055
28. Yayon, A., Klagsbrun, M., Esko, J. D., Leder, P., & Ornitz, D. M. (1991). Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell, 64(4), 841–848. https://doi.org/10.1016/0092-8674(91)90512-w
29. Schlessinger, J., Plotnikov, A. N., Ibrahimi, O. A., Eliseenkova, A. V., Yeh, B. K., Yayon, A., Linhardt, R. J., & Mohammadi, M. (2000b). Crystal Structure of a Ternary FGF-FGFR-Heparin Complex Reveals a Dual Role for Heparin in FGFR Binding and Dimerization. Molecular Cell, 6(3), 743–

750. https://doi.org/10.1016/s1097-2765(00)00073-3
30. Chung, I., Akita, R., Vandlen, R., Toomre, D., Schlessinger, J., & Mellman, I. (2010). Spatial control of EGF receptor activation by reversible dimerization on living cells. Nature, 464(7289), 783–787. https://doi.org/10.1038/nature08827
31. Soos, M. A., Field, C. E., & Siddle, K. (1993). Purified hybrid insulin/insulin-like growth factor-I receptors bind insulin-like growth factor-I, but not insulin, with high affinity. Biochemical Journal, 290(2), 419–426. https://doi.org/10.1042/bj2900419
32. Pandini, G., Frasca, F., Mineo, R., Sciacca, L., Vigneri, R., & Belfiore, A. (2002). Insulin/Insulin-like Growth Factor I Hybrid Receptors Have Different Biological Characteristics Depending on the Insulin Receptor Isoform Involved. Journal of Biological Chemistry, 277(42), 39684–39695. https://doi.org/10.1074/jbc.m202766200
33. Ogiso, H., Ishitani, R., Nureki, O., Fukai, S., Yamanaka, M., Kim, J. H., Saito, K., Sakamoto, A., Inoue, M., Shirouzu, M., & Yokoyama, S. (2002). Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular Domains. Cell, 110(6), 775–787. https://doi.org/10.1016/s0092-8674(02)00963-7
34. Stauber, D. J., DiGabriele, A. D., & Hendrickson, W. A. (2000b). Structural interactions of fibroblast growth factor receptor with its ligands. Proceedings of the National Academy of Sciences, 97(1), 49–54. https://doi.org/10.1073/pnas.97.1.49
35. Burgess, A. W., Cho, H. S., Eigenbrot, C., Ferguson, K. M., Garrett, T. P., Leahy, D. J., Lemmon, M. A., Sliwkowski, M. X., Ward, C. W., & Yokoyama, S. (2003). An Open-and-Shut Case? Recent Insights into the Activation of EGF/ErbB Receptors. Molecular Cell, 12(3), 541–552. https://doi.org/10.1016/s1097-2765(03)00350-2
36. Shewchuk, L. M., Hassell, A. M., Ellis, B., Holmes, W., Davis, R., Horne, E. L., Kadwell, S. H., McKee, D. D., & Moore, J. T. (2000). Structure of the Tie2 RTK Domain. Structure, 8(11), 1105–1113. https://doi.org/10.1016/s0969-2126(00)00516-5
37. Wybenga-Groot, L. E., Baskin, B., Ong, S. H., Tong, J., Pawson, T., & Sicheri, F. (2001). Structural Basis for Autoinhibition of the EphB2 Receptor Tyrosine Kinase by the Unphosphorylated Juxtamembrane Region. Cell, 106(6), 745–757. https://doi.org/10.1016/s0092-8674(01)00496-2
38. Huse, M., & Kuriyan, J. (2002). The Conformational Plasticity of Protein Kinases. Cell, 109(3), 275–282. https://doi.org/10.1016/s0092-8674(02)00741-9
39. Nolen, B., Taylor, S., & Ghosh, G. (2004). Regulation of Protein Kinases. Molecular Cell, 15(5), 661–675. https://doi.org/10.1016/j.molcel.2004.08.024
40. Mol, C. D., Dougan, D. R., Schneider, T. R., Skene, R. J., Kraus, M. L., Scheibe, D. N., Snell, G. P., Zou, H., Sang, B. C., & Wilson, K. P. (2004). Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine Kinase. Journal of Biological Chemistry, 279(30), 31655–31663. https://doi.org/10.1074/jbc.m403319200
41. Brewer, M. R., Choi, S. H., Alvarado, D., Moravcevic, K., Pozzi, A., Lemmon, M. A., & Carpenter, G. (2009b). The Juxtamembrane Region of the EGF Receptor Functions as an Activation Domain. Molecular Cell, 34(6), 641–651. https://doi.org/10.1016/j.molcel.2009.04.034
42. Jura, N., Endres, N. F., Engel, K., Deindl, S., Das, R., Lamers, M. H., Wemmer, D. E., Zhang, X., & Kuriyan, J. (2009). Mechanism for Activation of the EGF Receptor Catalytic Domain by the Juxtamembrane Segment. Cell, 137(7), 1293–1307. https://doi.org/10.1016/j.cell.2009.04.025
43. Brummer, T., Schmitz-Peiffer, C., & Daly, R. J. (2010b). Docking proteins. FEBS Journal, 277(21), 4356–4369. https://doi.org/10.1111/j.1742-4658.2010.07865.x
44. Hunter, T. (1995). Protein kinases and phosphatases: The Yin and Yang of protein phosphorylation and signaling. Cell, 80(2), 225–236. https://doi.org/10.1016/0092-8674(95)90405-0
45. Schenk, P. W., & Snaar-Jagalska, B. E. (1999). Signal perception and transduction: the role of protein kinases. Biochimica Et Biophysica Acta (BBA) - Molecular Cell

Research, 1449(1), 1–24. https://doi.org/10.1016/s0167-4889(98)00178-5
46. Heldin, C. H. (1995). Dimerization of cell surface receptors in signal transduction. Cell, 80(2), 213–223. https://doi.org/10.1016/0092-8674(95)90404-2
47. Östman, A. (2001b). Regulation of receptor tyrosine kinase signaling by protein tyrosine phosphatases. Trends in Cell Biology, 11(6), 258–266. https://doi.org/10.1016/s0962-8924(01)01990-0
48. Casaletto, J. B., & McClatchey, A. I. (2012). Spatial regulation of receptor tyrosine kinases in development and cancer. Nature Reviews. Cancer, 12(6), 387–400. https://doi.org/10.1038/nrc3277
49. McDonell, L. M., Kernohan, K. D., Boycott, K. M., & Sawyer, S. L. (2015). Receptor tyrosine kinase mutations in developmental syndromes and cancer: two sides of the same coin. Human Molecular Genetics, 24(R1), R60–R66. https://doi.org/10.1093/hmg/ddv254
50. Bertram, J. S. (2000). The molecular biology of cancer. Molecular Aspects of Medicine, 21(6), 167–223. https://doi.org/10.1016/s0098-2997(00)00007-8
51. Nishikawa, R., Ji, X. D., Harmon, R. C., Lazar, C. S., Gill, G. N., Cavenee, W. K., & Huang, H. J. (1994). A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proceedings of the National Academy of Sciences, 91(16), 7727–7731. https://doi.org/10.1073/pnas.91.16.7727
52. Zwick, E., Bange, J., & Ullrich, A. (2002). Receptor tyrosine kinases as targets for anticancer drugs. Trends in Molecular Medicine, 8(1), 17–23. https://doi.org/10.1016/s1471-4914(01)02217-1
53. Buchdunger, E., Matter, A., & Druker, B. J. (2001). Bcr-Abl inhibition as a modality of CML therapeutics. Biochimica Et Biophysica Acta (BBA) - Reviews on Cancer, 1551(1), M11–M18. https://doi.org/10.1016/s0304-419x(01)00022-1
54. Kolibaba, K. S., & Druker, B. J. (1997). Protein tyrosine kinases and cancer. Biochimica Et Biophysica Acta (BBA) - Reviews on Cancer, 1333(3), F217–F248. https://doi.org/10.1016/s0304-419x(97)00022-x
55. John, A. M., Thomas, N. S. B., Mufti, G. J., & Padua, R. A. (2004). Targeted therapies in myeloid leukemia. Seminars in Cancer Biology, 14(1), 41–62. https://doi.org/10.1016/j.semcancer.2003.11.006
56. Daley, G. Q., Van Etten, R. A., & Baltimore, D. (1990). Induction of Chronic Myelogenous Leukemia in Mice by the P210 bcr/abl Gene of the Philadelphia Chromosome. Science, 247(4944), 824–830. https://doi.org/10.1126/science.2406902
57. Goga, A., McLaughlin, J., Afar, D. E., Saffran, D. C., & Witte, O. N. (1995). Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene. Cell, 82(6), 981–988. https://doi.org/10.1016/0092-8674(95)90277-5
58. Golub, T. R., Barker, G. F., Lovett, M., & Gilliland, D. G. (1994). Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell, 77(2), 307–316. https://doi.org/10.1016/0092-8674(94)90322-0
59. Golub, T. R., McLean, T., Stegmaier, K., Carroll, M., Tomasson, M., & Gilliland, D. G. (1996). The TEL gene and human leukemia. Biochimica Et Biophysica Acta (BBA) - Reviews on Cancer, 1288(1), M7–M10. https://doi.org/10.1016/0304-419x(96)00015-7
60. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. (1995, September 1). PubMed. https://pubmed.ncbi.nlm.nih.gov/7655022/
61. Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung. (1990, November 1). PubMed. https://pubmed.ncbi.nlm.nih.gov/2208175/
62. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. (1993, May 15). PubMed. https://pubmed.ncbi.nlm.nih.gov/7683573/
63. Wong, A. J., Bigner, S. H., Bigner, D. D., Kinzler, K. W., Hamilton, S. R., & Vogelstein, B. (1987). Increased expression of the epidermal growth factor receptor gene

in malignant gliomas is invariably associated with gene amplification. Proceedings of the National Academy of Sciences, 84(19), 6899–6903. https://doi.org/10.1073/pnas.84.19.6899

64. Characterization and quantitation of the epidermal growth factor receptor in invasive and superficial bladder tumors. (1989, November 1). PubMed. https://pubmed.ncbi.nlm.nih.gov/2790793/
65. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. (1992b, June 1). PubMed. https://pubmed.ncbi.nlm.nih.gov/1317261/
66. Role for membrane and secreted insulin-like growth factor-binding protein-2 in the regulation of insulin-like growth factor action in lung tumors. (1993, October 1). PubMed. https://pubmed.ncbi.nlm.nih.gov/7691401/
67. Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer. (1998, March 15). PubMed. https://pubmed.ncbi.nlm.nih.gov/9515800/
68. Chan, J. M., Stampfer, M. J., Giovannucci, E., Gann, P. H., Ma, J., Wilkinson, P., Hennekens, C. H., & Pollak, M. (1998). Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study. Science, 279(5350), 563–566. https://doi.org/10.1126/science.279.5350.563
69. Koppal T Neglected kinase targets are now in vogue Drug Disc Develop 2003. Aug: 75-80
70. Bennasroune, A., Gardin, A., Aunis, D., Crémel, G., & Hubert, P. (2004). Tyrosine kinase receptors as attractive targets of cancer therapy. Critical Reviews in Oncology/Hematology, 50(1), 23–38. https://doi.org/10.1016/j.critrevonc.2003.08.004
71. Hubbard, S. (2002). Protein tyrosine kinases: autoregulation and small-molecule inhibition. Current Opinion in Structural Biology, 12(6), 735–741. https://doi.org/10.1016/s0959-440x(02)00383-4
72. Davies, S. P., Reddy, H., Caivano, M., & Cohen, P. (2000). Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochemical Journal, 351(1), 95. https://doi.org/10.1042/0264-6021:3510095
73. Fabbro, D., Ruetz, S., Buchdunger, E., Cowan-Jacob, S. W., Fendrich, G., Liebetanz, J., Mestan, J., O'Reilly, T., Traxler, P., Chaudhuri, B., Fretz, H., Zimmermann, J., Meyer, T., Caravatti, G., Furet, P., & Manley, P. W. (2002). Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Pharmacology & Therapeutics, 93(2–3), 79–98. https://doi.org/10.1016/s0163-7258(02)00179-1
74. Yaish, P., Gazit, A., Gilon, C., & Levitzki, A. (1988). Blocking of EGF-Dependent Cell Proliferation by EGF Receptor Kinase Inhibitors. Science, 242(4880), 933–935. https://doi.org/10.1126/science.3263702
75. Fabbro, D. (2002). Protein tyrosine kinase inhibitors: new treatment modalities? Current Opinion in Pharmacology, 2(4), 374–381. https://doi.org/10.1016/s1471-4892(02)00179-0
76. Gazit, A., Yaish, P., Gilon, C., & Levitzki, A. (1989b). Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors. Journal of Medicinal Chemistry, 32(10), 2344–2352. https://doi.org/10.1021/jm00130a020
77. Levitzki, A. (2002). Tyrosine kinases as targets for cancer therapy. European Journal of Cancer, 38, S11–S18. https://doi.org/10.1016/s0959-8049(02)80598-6
78. Druker, B. J. (2002). STI571 (GleevecTM) as a paradigm for cancer therapy. Trends in Molecular Medicine, 8(4), S14–S18. https://doi.org/10.1016/s1471-4914(02)02305-5
79. Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J. Y., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., Eek, R., Horai, T., Noda, K., Takata, I., Smit, E., Averbuch, S., Macleod, A., Feyereislova, A., Dong, R. P., & Baselga, J. (2003). Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 21(12), 2237–2246. https://doi.org/10.1200/jco.2003.10.038
80. Neshat, M. S., Mellinghoff, I. K., Tran, C., Stiles, B., Thomas, G., Petersen, R., Frost, P., Gibbons, J. J., Wu, H., & Sawyers, C. L. (2001). Enhanced sensitivity of PTEN-

deficient tumors to inhibition of FRAP/mTOR. Proceedings of the National Academy of Sciences, 98(18), 10314–10319. https://doi.org/10.1073/pnas.171076798
81. Houshmand, P., & Zlotnik, A. (2003). Targeting tumor cells. Current Opinion in Cell Biology, 15(5), 640–644. https://doi.org/10.1016/s0955-0674(03)00106-6
82. Craven, R. J., Lightfoot, H., & Cance, W. G. (2003). A decade of tyrosine kinases: from gene discovery to therapeutics. Surgical Oncology, 12(1), 39–49. https://doi.org/10.1016/s0960-7404(03)00004-5
83. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987). Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene. Science, 235(4785), 177–182. https://doi.org/10.1126/science.3798106
84. Guy, C. T., Cardiff, R. D., & Muller, W. J. (1996). Activated neu Induces Rapid Tumor Progression. Journal of Biological Chemistry, 271(13), 7673–7678. https://doi.org/10.1074/jbc.271.13.7673
85. Izumi, Y., Xu, L., Di Tomaso, E., Fukumura, D., & Jain, R. K. (2002). Herceptin acts as an anti-angiogenic cocktail. Nature, 416(6878), 279–280. https://doi.org/10.1038/416279b
86. Fischer, O. M., Streit, S., Hart, S., & Ullrich, A. (2003). Beyond Herceptin and Gleevec. Current Opinion in Chemical Biology, 7(4), 490–495. https://doi.org/10.1016/s1367-5931(03)00082-6
87. Bukau, B., & Horwich, A. L. (1998). The Hsp70 and Hsp60 Chaperone Machines. Cell, 92(3), 351–366. https://doi.org/10.1016/s0092-8674(00)80928-9
88. Hartl, F. U. (1996). Molecular chaperones in cellular protein folding. Nature, 381(6583), 571–580. https://doi.org/10.1038/381571a0
89. Yarden, Y., & Sliwkowski, M. X. (2001). Untangling the ErbB signalling network. Nature Reviews Molecular Cell Biology, 2(2), 127–137. https://doi.org/10.1038/35052073
90. Sreedhar, A. S., Soti, C., & Csermely, P. (2004). Inhibition of Hsp90: a new strategy for inhibiting protein kinases. Biochimica Et Biophysica Acta (BBA) - Proteins and Proteomics, 1697(1–2), 233–242. https://doi.org/10.1016/j.bbapap.2003.11.027
91. Workman, P., & Kaye, S. B. (2002). Translating basic cancer research into new cancer therapeutics. Trends in Molecular Medicine, 8(4), S1–S9. https://doi.org/10.1016/s1471-4914(02)02319-5
92. Colaco, C. A. (2003). Cancer immunotherapy: simply cell biology? Trends in Molecular Medicine, 9(12), 515–516. https://doi.org/10.1016/j.molmed.2003.10.006
93. Kreitman, R. J. (1999). Immunotoxins in cancer therapy. Current Opinion in Immunology, 11(5), 570–578. https://doi.org/10.1016/s0952-7915(99)00005-9
94. Bexxar (Corixa/GlaxoSmithKline). (2002, January 1). PubMed. https://pubmed.ncbi.nlm.nih.gov/12054068/
95. Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion. (1992, February 1). PubMed. https://pubmed.ncbi.nlm.nih.gov/1370636/
96. Payne, G. (2003). Progress in immunoconjugate cancer therapeutics. Cancer Cell, 3(3), 207–212. https://doi.org/10.1016/s1535-6108(03)00057-6
97. Andrews, D. W., Resnicoff, M., Flanders, A. E., Kenyon, L., Curtis, M., Merli, G., Baserga, R., Iliakis, G., & Aiken, R. D. (2001). Results of a Pilot Study Involving the Use of an Antisense Oligodeoxynucleotide Directed Against the Insulin-Like Growth Factor Type I Receptor in Malignant Astrocytomas. Journal of Clinical Oncology, 19(8), 2189–2200. https://doi.org/10.1200/jco.2001.19.8.2189
98. Liu, W. Q., Vidal, M., Gresh, N., Roques, B. P., & Garbay, C. (1999). Small Peptides Containing Phosphotyrosine and Adjacent αMe-Phosphotyrosine or Its Mimetics as Highly Potent Inhibitors of Grb2 SH2 Domain. Journal of Medicinal Chemistry, 42(18), 3737–3741. https://doi.org/10.1021/jm9911074
99. Berezov, A., Chen, J., Liu, Q., Zhang, H. T., Greene, M. I., & Murali, R. (2002). Disabling Receptor Ensembles with Rationally Designed Interface Peptidomimetics. Journal of Biological Chemistry, 277(31), 28330–28339. https://doi.org/10.1074/jbc.m202880200

100. Cohen, P. (1999). The development and therapeutic potential of protein kinase inhibitors. Current Opinion in Chemical Biology, 3(4), 459–465. https://doi.org/10.1016/s1367-5931(99)80067-2
101. Hanahan, D., & Folkman, J. (1996). Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis. Cell, 86(3), 353–364. https://doi.org/10.1016/s0092-8674(00)80108-7
102. Kerbel, R. S. (1997). A cancer therapy resistant to resistance. Nature, 390(6658), 335–336. https://doi.org/10.1038/36978
103. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. (1999, January 1). PubMed. https://pubmed.ncbi.nlm.nih.gov/9892193/
104. Mohammadi, M., Froum, S., Hamby, J. M., Schroeder, M. C., Panek, R. L., Lu, G. H., Eliseenkova, A. V., Green, D., Schlessinger, J., & Hubbard, S. R. (1998). Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. The EMBO Journal, 17(20), 5896–5904. https://doi.org/10.1093/emboj/17.20.5896
105. Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J., & Saltiel, A. R. (1995). A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proceedings of the National Academy of Sciences, 92(17), 7686–7689. https://doi.org/10.1073/pnas.92.17.7686
106. Boehm, T., Folkman, J., Browder, T., & O'Reilly, M. S. (1997). Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature, 390(6658), 404–407. https://doi.org/10.1038/37126
107. Chen, H. Y., Brady, D. C., & Villanueva, J. (2016). Double Trouble: Kinase domain duplication as a new path to drug resistance. Pigment Cell & Melanoma Research, 29(5), 493–495. https://doi.org/10.1111/pcmr.12508
108. Gallant, J. N., Sheehan, J. H., Shaver, T. M., Bailey, M., Lipson, D., Chandramohan, R., Brewer, M. R., York, S. J., Kris, M. G., Pietenpol, J. A., Ladanyi, M., Miller, V. A., Ali, S. M., Meiler, J., & Lovly, C. M. (2015). EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib. Cancer Discovery, 5(11), 1155–1163. https://doi.org/10.1158/2159-8290.cd-15-0654
109. Rodriguez, F. J., Ligon, A. H., Horkayne-Szakaly, I., Rushing, E. J., Ligon, K. L., Vena, N., Garcia, D. I., Cameron, J. D., & Eberhart, C. G. (2012). BRAFDuplications and MAPK Pathway Activation Are Frequent in Gliomas of the Optic Nerve Proper. Journal of Neuropathology & Experimental Neurology, 71(9), 789–795. https://doi.org/10.1097/nen.0b013e3182656ef8
110. Klempner, S. J., Bordoni, R., Gowen, K., Kaplan, H., Stephens, P. J., Ou, S. H. I., & Ali, S. M. (2016). Identification ofBRAFKinase Domain Duplications Across Multiple Tumor Types and Response to RAF Inhibitor Therapy. JAMA Oncology, 2(2), 272. https://doi.org/10.1001/jamaoncol.2015.4437
111. Gay, L., Pavlick, D., Chung, J., Ramkissoon, S., Daniel, S., Elvin, J., Severson, E., Bivona, T., Reckamp, K., Klempner, S., Ou, S. H., Schrock, A., Miller, V., Stephens, P., Ross, J., Ganesan, S., Lovly, C., Mansfield, A., & Ali, S. (2017). Genomic profiling of 114,200 advanced cancers identifies recurrent kinase domain duplications (KDD) and oncogenic rearrangements (RE) across diverse tumor types. Annals of Oncology, 28, v595. https://doi.org/10.1093/annonc/mdx391
112. Kondrashov, F. A. (2012). Gene duplication as a mechanism of genomic adaptation to a changing environment. Proceedings of the Royal Society B Biological Sciences, 279(1749), 5048–5057. https://doi.org/10.1098/rspb.2012.1108
113. Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., Salton, M., Dahlman, K. B., Tadi, M., Wargo, J. A., Flaherty, K. T., Kelley, M. C., Misteli, T., Chapman, P. B., Sosman, J. A., . . . Solit, D. B. (2011). RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature, 480(7377), 387–390. https://doi.org/10.1038/nature10662

114. Kwak, E. L., Bang, Y. J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., Varella-Garcia, M., Kim, W. H., Lynch, T. J., Fidias, P., Stubbs, H., Engelman, J. A., Sequist, L. V., Tan, W., Gandhi, L., . . . Iafrate, A. J. (2010). Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer. New England Journal of Medicine, 363(18), 1693–1703. https://doi.org/10.1056/nejmoa1006448

115. Mok, T. S., Wu, Y. L., Thongprasert, S., Yang, C. H., Chu, D. T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., Nishiwaki, Y., Ohe, Y., Yang, J. J., Chewaskulyong, B., Jiang, H., Duffield, E. L., Watkins, C. L., Armour, A. A., & Fukuoka, M. (2009). Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma. New England Journal of Medicine, 361(10), 947–957. https://doi.org/10.1056/nejmoa0810699

116. Shawver, L. K., Slamon, D., & Ullrich, A. (2002). Smart drugs: Tyrosine kinase inhibitors in cancer therapy. Cancer Cell, 1(2), 117–123. https://doi.org/10.1016/s1535-6108(02)00039-9

117. Pirker, R., Pereira, J. R., Szczesna, A., Von Pawel, J., Krzakowski, M., Ramlau, R., Vynnychenko, I., Park, K., Yu, C. T., Ganul, V., Roh, J. K., Bajetta, E., O'Byrne, K., De Marinis, F., Eberhardt, W., Goddemeier, T., Emig, M., Gatzemeier, U., Renseigné, N., & Chouaid, C. (2009). Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. The Lancet, 373(9674), 1525–1531. https://doi.org/10.1016/s0140-6736(09)60569-9

118. Gibson, T. B., Ranganathan, A., & Grothey, A. (2006). Randomized Phase III Trial Results of Panitumumab, a Fully Human Anti—Epidermal Growth Factor Receptor Monoclonal Antibody, in Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 6(1), 29–31. https://doi.org/10.3816/ccc.2006.n.01

119. Vermorken, J. B., Mesia, R., Rivera, F., Remenar, E., Kawecki, A., Rottey, S., Erfan, J., Zabolotnyy, D., Kienzer, H. R., Cupissol, D., Peyrade, F., Benasso, M., Vynnychenko, I., De Raucourt, D., Bokemeyer, C., Schueler, A., Amellal, N., & Hitt, R. (2008). Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer. New England Journal of Medicine, 359(11), 1116–1127. https://doi.org/10.1056/nejmoa0802656

120. Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., Swain, S. M., Pisansky, T. M., Fehrenbacher, L., Kutteh, L. A., Vogel, V. G., Visscher, D. W., Yothers, G., Jenkins, R. B., Brown, A. M., . . . Wolmark, N. (2005). Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer. New England Journal of Medicine, 353(16), 1673–1684. https://doi.org/10.1056/nejmoa052122

121. Von Minckwitz, G., Procter, M., De Azambuja, E., Zardavas, D., Benyunes, M., Viale, G., Suter, T., Arahmani, A., Rouchet, N., Clark, E., Knott, A., Lang, I., Levy, C., Yardley, D. A., Bines, J., Gelber, R. D., Piccart, M., & Baselga, J. (2017). Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. New England Journal of Medicine, 377(2), 122–131. https://doi.org/10.1056/nejmoa1703643

122. Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005). EGFRMutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib. New England Journal of Medicine, 352(8), 786–792. https://doi.org/10.1056/nejmoa044238

123. Sasaki, T., Koivunen, J., Ogino, A., Yanagita, M., Nikiforow, S., Zheng, W., Lathan, C., Marcoux, J. P., Du, J., Okuda, K., Capelletti, M., Shimamura, T., Ercan, D., Stumpfova, M., Xiao, Y., Weremowicz, S., Butaney, M., Heon, S., Wilner, K., . . . Jänne, P. A. (2011). A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors. Cancer Research, 71(18), 6051–6060. https://doi.org/10.1158/0008-5472.can-11-1340

124. Engelman, J. A., Jänne, P. A., Mermel, C., Pearlberg, J., Mukohara, T., Fleet, C., Cichowski, K., Johnson, B. E., & Cantley, L. C. (2005). ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proceedings of the National

Academy of Sciences, 102(10), 3788–3793. https://doi.org/10.1073/pnas.0409773102

125. Hrustanovic, G., Olivas, V., Pazarentzos, E., Tulpule, A., Asthana, S., Blakely, C. M., Okimoto, R. A., Lin, L., Neel, D. S., Sabnis, A., Flanagan, J., Chan, E., Varella-Garcia, M., Aisner, D. L., Vaishnavi, A., Ou, S. H. I., Collisson, E. A., Ichihara, E., Mack, P. C., . . . Bivona, T. G. (2015). RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK–positive lung cancer. Nature Medicine, 21(9), 1038–1047. https://doi.org/10.1038/nm.3930
126. Blakely, C. M., Pazarentzos, E., Olivas, V., Asthana, S., Yan, J. J., Tan, I., Hrustanovic, G., Chan, E., Lin, L., Neel, D. S., Newton, W., Bobb, K. L., Fouts, T. R., Meshulam, J., Gubens, M. A., Jablons, D. M., Johnson, J. R., Bandyopadhyay, S., Krogan, N. J., & Bivona, T. G. (2015). NF-κB-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer. Cell Reports, 11(1), 98–110. https://doi.org/10.1016/j.celrep.2015.03.012
127. Li, D., Ambrogio, L., Shimamura, T., Kubo, S., Takahashi, M., Chirieac, L. R., Padera, R. F., Shapiro, G. I., Baum, A., Himmelsbach, F., Rettig, W. J., Meyerson, M., Solca, F., Greulich, H., & Wong, K. K. (2008). BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene, 27(34), 4702–4711. https://doi.org/10.1038/onc.2008.109
128. Kwak, E. L., Sordella, R., Bell, D. W., Godin-Heymann, N., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Driscoll, D. R., Fidias, P., Lynch, T. J., Rabindran, S. K., McGinnis, J. P., Wissner, A., Sharma, S. V., Isselbacher, K. J., Settleman, J., & Haber, D. A. (2005). Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proceedings of the National Academy of Sciences, 102(21), 7665–7670. https://doi.org/10.1073/pnas.0502860102
129. Finlay, M. R. V., Anderton, M., Ashton, S., Ballard, P., Bethel, P. A., Box, M. R., Bradbury, R. H., Brown, S. J., Butterworth, S., Campbell, A., Chorley, C., Colclough, N., Cross, D. a. E., Currie, G. S., Grist, M., Hassall, L., Hill, G. B., James, D., James, M., Wrigley, G. L. (2014). Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor. Journal of Medicinal Chemistry, 57(20), 8249–8267. https://doi.org/10.1021/jm500973a
130. Soria, J. C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., Okamoto, I., Zhou, C., Cho, B. C., Cheng, Y., Cho, E. K., Voon, P. J., Planchard, D., Su, W. C., Gray, J. E., . . . Ramalingam, S. S. (2018). Osimertinib in UntreatedEGFR-Mutated Advanced Non–Small-Cell Lung Cancer. New England Journal of Medicine, 378(2), 113–125. https://doi.org/10.1056/nejmoa1713137
131. Janjigian, Y. Y., Smit, E. F., Groen, H. J., Horn, L., Gettinger, S., Camidge, D. R., Riely, G. J., Wang, B., Fu, Y., Chand, V. K., Miller, V. A., & Pao, W. (2014). Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor–Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations. Cancer Discovery, 4(9), 1036–1045. https://doi.org/10.1158/2159-8290.cd-14-0326

How to cite this article: Aruna Rajeswari, Balaprakash Bhavani. The role of tyrosine kinases in cancer: signal transduction mechanisms and therapeutic targets. *Int J Health Sci Res.* 2024; 14(9):320-336. DOI: *https://doi.org/10.52403/ijhsr.20240942*

******